Barclays upgraded CVS Health Inc CVS on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by share gains, with further upside potential from CostVantage.Despite macroeconomic pressures impacting the retail pharmacy sector, the analyst writes that CVS has shown resilience thanks to its diversified business model.Also Read: CVS, UnitedHealth Request FTC Chair Recusal Amid Ongoing Pharmacy Benefit Managers Lawsuit.This has allowed the company to mitigate some of these challenges and c ...

Core Insights - Robinhood Markets announced its first investor day scheduled for December 4, where it will discuss its long-term vision and strategies to enhance customer and shareholder value [1] - Barclays raised its price target for Robinhood from $20 to $23, citing ongoing business momentum and expected growth in transaction revenues [2] - Shares of Robinhood have nearly doubled in 2024, reflecting strong market performance and investor interest [1][2] Company Developments - The investor day will take place in New York City, allowing executives to engage with investors and analysts [1] - Barclays analysts anticipate that transaction revenues will exceed Wall Street estimates by 5% in the upcoming quarters [2] - CEO Vlad Tenev is expected to introduce new products at the upcoming "HOOD Summit" on October 16 [2] Market Performance - Robinhood's stock experienced an approximately 8% increase on the day of the announcement, contributing to its year-to-date gains [2] - The stock price reached $25.01, reflecting a 7.23% increase on the trading day [3]

Key TakeawaysStellantis reported U.S. sales slumped 20% year-over-year in the third quarter as all of its brands except Fiat posted declines.The automaker will continue to offer incentives begun in the beginning of the quarter through the rest of the year.Barclays analysts downgraded the stock, saying they see no sign of recovery until the first half of next year at the earliest. Stellantis (STLA) shares fell Thursday after the automaker's U.S. unit reported a big drop in sales as all but one of its brands ...

Core Insights - Perimeter Medical Imaging AI, Inc. has developed the Perimeter B-Series OCT system, which integrates AI with optical coherence tomography for margin assessment during breast-conserving surgeries, aiming to reduce high reoperation rates associated with breast cancer surgeries [1][4] Group 1: Clinical Trial and Results - A pivotal study has completed patient enrollment, involving approximately 530 women undergoing breast-conserving surgery for Stage 0-III invasive ductal carcinoma [2][3] - The primary endpoint of the trial is to evaluate the occurrence of unaddressed positive margins, with a within-subject analysis planned [3] - Results from the pivotal trial are expected in Q4-2024, which could support a submission to the FDA in 2025 [1][4] Group 2: Market Implications - If successful, the B-Series OCT system could receive the first-ever marketing clearance for specific use in breast tissue and margin evaluation, representing a significant milestone for Perimeter's business [1][4] - The technology aims to empower surgeons with real-time intraoperative tools to improve margin assessment and potentially lower re-excision rates, setting a new standard in specimen imaging technology [4] Group 3: Financial and Operational Context - The company has received a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas to support the clinical trial [6] - The Perimeter S-Series OCT system is already FDA-cleared for general indications, while the B-Series is currently investigational and not available for sale in the U.S. [6][7]

Investors interested in stocks from the Banks - Foreign sector have probably already heard of Barclays (BCS) and Nordea Bank AB (NRDBY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that target ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they bel ...

To control inflation, the Fed raised interest rates for 10 straight policy meetings before finally opting for a rate pause in June 2023. It barely raised rates till the end of 2023 and promised at least three rate cuts in 2024. However, it is only in September of this year that we are finally going to see the first slashing of rates.Fed Chair Jerome Powell has continued to suggest that he is fairly certain of rate cuts this year, but the Fed would embark on that journey only after reviewing further data. Fr ...

Barclays PLC (BCS) has been facing challenges to sell a stake in its U.K. merchant payments unit due to varied opinions on that business’ valuation, four people with knowledge of the matter informed Reuters.What Makes This Pursuit Challenging for Barclays?According to two of the sources, Brookfield was among the private equity firms that withdrew from bidding in recent months due to BCS’s high asking price. Other sources mentioned that negotiations have been complicated by the acquisition of Takepayments, o ...

Barclays is reportedly having trouble unloading a stake in its U.K. merchant payments unit.That’s according to a report Friday (Sept. 13) by Reuters, which cited sources who say the difficulty is down to differing views on that business’s valuation.Brookfield, which manages more than $825 billion in assets, was one of the private equity firms that walked away from bidding in recent months, chiefly because of Barclays’ asking price, two of the sources said.Other sources said that the negotiations have been c ...

Group 1 - Goldman Sachs and Barclays have reached a deal for Goldman to sell a $2 billion portfolio of loans made to General Motors customers at a discount [1] - Goldman Sachs CEO David Solomon indicated that the bank expects to incur a $400 million loss from the transition of the GM card platform and other retail ventures [1] - The transaction reflects Goldman Sachs' ongoing retreat from retail banking, which has faced losses and regulatory scrutiny [1] Group 2 - Goldman Sachs is still in the process of selling its portfolio of loans tied to Apple, another credit card partnership [2] - Barclays aims to add $10 billion in assets related to the business in the coming years [2] - The GM credit card program has experienced high charge-off rates, with over 10% on Goldman-originated accounts, compared to an annualized charge-off rate of 4.5% for American commercial banks [2] Group 3 - Goldman Sachs has been pivoting away from Main Street banking, having sold GreenSky and "substantially all" of the Marcus loans a year ago [3] - The bank has also reached an agreement with Betterment for the acquisition of Marcus Invest's digital investment accounts [3] - These changes indicate Goldman Sachs' focus on investments, banking, and market-oriented activities [3]